Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
173.92
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
March 04, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
March 02, 2024
Getting its Alzheimer's medicine approved in the European Union could be big.
Via
The Motley Fool
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
February 29, 2024
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.
Via
Benzinga
Biogen Unusual Options Activity
February 29, 2024
Via
Benzinga
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
February 24, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
February 23, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024
From
Biogen Inc.
Via
GlobeNewswire
Peering Into Biogen's Recent Short Interest
February 19, 2024
Via
Benzinga
Breaking Down Biogen: 8 Analysts Share Their Views
February 13, 2024
Via
Benzinga
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
February 22, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
February 21, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
February 19, 2024
Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential.
Via
InvestorPlace
Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit
February 13, 2024
The company missed both sales and earnings expectations for the fourth quarter.
Via
Investor's Business Daily
Looking At Biogen's Recent Unusual Options Activity
February 12, 2024
Via
Benzinga
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
February 14, 2024
Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties.
Via
Benzinga
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
February 14, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Biogen (BIIB) Q4 2023 Earnings Call Transcript
February 13, 2024
BIIB earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?
February 13, 2024
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why Is Biogen Stock Trading Lower On Tuesday?
February 13, 2024
Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs.
Via
Benzinga
Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch
February 13, 2024
Despite the Fed rhetoric about the inflation fight being still on, the central bank will likely cut rates this year, an analyst said.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024
From
Biogen Inc.
Via
GlobeNewswire
Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years
February 09, 2024
Via
Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
Via
Benzinga
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
February 12, 2024
For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks.
Via
InvestorPlace
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.
Via
Benzinga
Exposures
Product Safety
Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024
From
Biogen Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.